Estée Lauder Shares Seen as Undervalued Amid Sales Recovery
Estée Lauder posts first organic sales growth in three years, with analysts flagging shares as a bargain despite prior headwinds.
Estée Lauder appears to be turning a corner after an extended period of declining organic sales, with Morningstar analysts pointing to a projected 3% revenue increase in fiscal 2026 as evidence that the beauty giant's recovery is gaining traction.
The company's adjusted gross margin has also shown improvement, a development analysts say reflects disciplined cost management alongside ongoing investment in its portfolio of prestige brands. Those brand-building outlays, rather than being viewed as a drag on near-term profitability, are characterized as a strategic lever likely to reinforce Estée Lauder's competitive moat over time.
Read more Kodiak AI Insider Files Form 144 as KDK Shares Drop Nearly 10% →
The recovery narrative carries added weight given that the company endured roughly three consecutive years of organic sales contraction — a stretch that weighed heavily on investor sentiment and depressed the stock. Analysts now argue that the market has not fully priced in the improving fundamentals, leaving shares at levels they describe as a bargain relative to intrinsic value.
The combination of returning top-line growth, margin expansion, and sustained brand investment positions Estée Lauder to reassert itself in the premium beauty segment, where it competes against global rivals for shelf space and consumer loyalty. Whether the fiscal 2026 sales projection materializes will be a closely watched test of management's turnaround execution.
Continue reading at Morningstar.
